U.S. License Holder:
Amneal / mAbxience
Date of License:
ALYMSYS (bevacizumab-maly) is a vascular endothelial growth factor inhibitor indicated for the treatment of:
Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment;
Metastatic colorectal cancer, in combination with fluoropyrimidine- irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In The E.U.
Alymsys® (mAbxience) (March-2021)